Australia's Dimerix hits 7-month high on $4.8 billion sale

Dimerix

22/12/2025 04:10

** Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months

** Stock touches its biggest intraday pct gain in six months, if gains hold

** Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion

** Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases

** Stock up 80.89% YTD, including session's moves

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))